

DEOpen announces its Scientific Advisory Board

06 May 2019 | News | By Sonali Wankhade

Initiated through a partnership between WuXi AppTec. and leading academic and research institutions, the goal of the platform is to provide open access to DEL libraries for new drug discovery projects to a broader range of users than ever before



DEOpen, a new platform dedicated to the hit generation of drug discovery of DNA Encoded Library (DEL) Technology, has announced the formation of its Scientific Advisory Board.

The board, chaired by Dr. Richard Lerner, Institute Professor of Scripps Research, and composed of diverse members from prestigious research institutions and industry globally, will set the direction and guide the development of DEOpen in its vision to advance the adoption of DNA encoded library technology in new drug discovery.

Initiated through a partnership between WuXi AppTec. and leading academic and research institutions, the goal of the platform is to provide open access to DEL libraries for new drug discovery projects to a broader range of users than ever before. On the DEOpen platform, providers offer access to their libraries, while users can access the libraries and build relationships with a variety of library and service providers.

Dr. Lerner stated, "We aim to be a bridge between academia and industry and jointly promote the application of DEL technology in the field of new drug discovery."

Developed using block chain technology, DEOpen offers maximum IP protection for users who utilize the power of the online platform. "We envision the new platform will unlock the true potential of DEL technology," said board member Dr. Richard Soll of WuXi AppTec, "while simultaneously providing full protection of intellectual property for both user and technology provider."

In addition to Chairman Dr. Lerner, the committee consists of the following other esteemed members: Phil Baran, Ph.D. of Scripps Research; Carolyn Bertozzi, Ph.D. of Stanford University; Professor Raymond A. Dwek, CBE, FRS of the University of Oxford; Martin Friedlander, M.D. Ph.D. of Scripps Research; Michael Kaplitt, M.D, Ph.D of Weill Cornell Medical College; Roger Kornberg, Ph.D. of Stanford University School of Medicine; Casey Krusemark, Ph.D. of Purdue University College of Pharmacy; David R. Liu, Ph.D. of the Broad Institute of Harvard & MIT; Alan Saghatelian, Ph.D. of Salk Institute for Biological

Studies; Barry Sharpless, Ph.D. of Scripps Research; Richard Soll, Ph.D. of WuXi AppTec; and Chi-Huey Wong, Ph.D. of Scripps Research.